The global Biological Safety Testing Market was valued at USD 4.32 billion in 2022, with a projected CAGR of 13% during the forecast period to reach USD 12.98 billion in 2032. The growth of the biologics and biosimilars market in the pharmaceutical and biotechnology sectors is the major factor driving revenue growth. Rising incidences of chronic diseases, including cancer and autoimmune...